CoChat
Sign Up
Cited by 119

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects

Imtiaz, Saiqa, Ferdous, Umme Tamanna, Nizela, Alexis, Hasan, Anwarul, Shakoor, Adnan, Zia, Abdul Wasy, Uddin, Shihab·2025·European Journal of Medicinal Chemistry
DOI 10.1016/j.ejmech.2025.117535
Open this paper in CoChat — free account

Abstract

Cancer drug delivery remains a critical challenge with systemic toxicity, poor drug bioavailability, and a lack of effective targeting. Overcoming these barriers is essential for improving treatment efficacy and patient outcomes. This review discusses current drug delivery techniques that reshape cancer therapy by offering precise, controlled-release tailored to tumor-specific features. Innovations in nanotechnology, immunotherapy, and gene therapy enable interventions at molecular and cellular levels. Radiomics and pathomics integrate high-dimensional data to optimize diagnostics and treatment planning. Combination therapy addresses the complexities of tumor heterogeneity by synergizing multiple agents within a single therapeutic framework, while peptide-drug conjugates enhance specificity and potency. Hydrogel-based systems and microneedle arrays offer localized, sustained release, significantly improving therapeutic outcomes. However, clinical translation of these advancements faces significant barriers such as drug resistance, off-target effects, scalability, cost, and ethical concerns. Moreover, regulatory complexities and the economic feasibility of these therapies highlight the need for innovative frameworks to make them accessible globally. Therefore, there is a need for innovation in gene and cell therapy, next-generation drug delivery platforms, and personalized medicine. This review focuses on recent advancements in drug delivery techniques over the past decade, ev…

Overview

Integrity signals

Registry

Crossref · 10.1016/j.ejmech.2025.117535

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 160

  1. Biemar, 2013, Global progress against cancer-challenges and opportunities, Cancer Biol. Med.
  2. Naser, 2022, A guide through conventional and modern cancer treatment modalities: a specific focus on glioblastoma cancer therapy, Oncol. Rep., 10.3892/or.2022.8405 · DOI
  3. Anik, 2022, Role of reactive oxygen species in aging and age-related diseases: a review, ACS Appl. Bio Mater., 5, 4028, 10.1021/acsabm.2c00411 · DOI
  4. Uddin, 2022, Transdermal delivery of antigenic protein using ionic liquid-based nanocarriers for tumor immunotherapy, ACS Appl. Bio Mater., 6, 2586, 10.1021/acsabm.2c00061 · DOI
  5. Nel, 2023, Functionalized liposomes for targeted breast cancer drug delivery, Bioact. Mater.
  6. Shoudho, 2024, Influence of physicochemical properties of iron oxide nanoparticles on their antibacterial activity, ACS Omega, 9, 33303, 10.1021/acsomega.4c02822 · DOI
  7. Behera, 2020, Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review, Environ. Chem. Lett., 10.1007/s10311-020-01022-9 · DOI
  8. Mahmud, 2022, Advances in nanomaterial-based platforms to combat COVID-19 : diagnostics , preventions , therapeutics , and vaccine developments, ACS Appl. Bio Mater., 6, 2431, 10.1021/acsabm.2c00123 · DOI
  9. Li, 2023, Recent advances in targeted drug delivery strategy for enhancing oncotherapy, Pharmaceutics
  10. Rahim, 2021, Recent advancements in stimuli responsive drug delivery platforms for active and passive cancer targeting, Cancers, 10.3390/cancers13040670 · DOI
  11. Pucci, 2019, Innovative approaches for cancer treatment: current perspectives and new challenges, Ecancermedicalscience, 13, 1, 10.3332/ecancer.2019.961 · DOI
  12. Su, 2023, Nanomedicine strategies for targeting tumor stroma, Cancers, 10.3390/cancers15164145 · DOI
  13. Okuyama, 2016, Recent advances and future challenges in cancer immunotherapy, Rinsho Ketsueki, 57, 2388
  14. Rayati, 2024, Gene therapy in glioblastoma multiforme: can it be a role changer?, Heliyon, 10.1016/j.heliyon.2024.e27087 · DOI
  15. Bülow, 2023, Extending the landscape of omics technologies by pathomics, npj Syst. Biol. Appl., 10.1038/s41540-023-00301-9 · DOI
  16. HajiEsmailPoor, 2023, Radiomics diagnostic performance in predicting lymph node metastasis of papillary thyroid carcinoma: a systematic review and meta-analysis, Eur. J. Radiol., 10.1016/j.ejrad.2023.111129 · DOI
  17. Fan, 2023, The progress of combination therapy with immune checkpoint inhibitors in breast cancer, Biocell, 10.32604/biocell.2023.028516 · DOI
  18. Wang, 2023, Poly ethylene glycol (PEG)-Based hydrogels for drug delivery in cancer therapy: a comprehensive review, Adv. Healthcare Mater.
  19. Amarnani, 2022, Microneedles in diagnostic, treatment and theranostics: an advancement in minimally-invasive delivery system, Biomed. Microdevices, 10.1007/s10544-021-00604-w · DOI
  20. Hafeez, 2021, Challenges towards targeted drug delivery in cancer nanomedicines, Processes, 10.3390/pr9091527 · DOI
  21. Neoptolemos, 2024, Personalized treatment in localized pancreatic cancer, Eur. Surg. - Acta Chir. Austriaca., 10.1007/s10353-023-00814-x · DOI
  22. Chen, 2023, Current understanding of passive and active targeting nanomedicines to enhance tumor accumulation, Coord. Chem. Rev., 10.1016/j.ccr.2023.215051 · DOI
  23. Alavi, 2019, Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles, Drug Metab. Pers. Ther, 10.1515/dmpt-2018-0032 · DOI
  24. Kang, 2020, Size-dependent EPR effect of polymeric nanoparticles on tumor targeting, Adv. Healthcare Mater., 10.1002/adhm.201901223 · DOI
  25. Gu, 2021, Actively targeted nanomedicines for precision cancer therapy: concept, construction, challenges and clinical translation, J. Contr. Release, 329, 676, 10.1016/j.jconrel.2020.10.003 · DOI
  26. Kue, 2016, Small molecules for active targeting in cancer, Med. Res. Rev., 10.1002/med.21387 · DOI
  27. Vanderburgh, 2020, Tuning ligand density to optimize pharmacokinetics of targeted nanoparticles for dual protection against tumor-induced bone destruction, ACS Nano, 10.1021/acsnano.9b04571 · DOI
  28. Zhang, 2020, Strategies and challenges to improve the performance of tumor-associated active targeting, J. Mater. Chem. B
  29. Jia, 2021, Advances in multiple stimuli-responsive drug-delivery systems for cancer therapy, Int. J. Nanomed., 10.2147/IJN.S293427 · DOI
  30. Zhang, 2022, Stimuli-responsive nanoparticles for controlled drug delivery in synergistic cancer immunotherapy, Adv. Sci.
  31. Puccetti, 2024, Biologics, theranostics, and personalized medicine in drug delivery systems, Pharmacol. Res., 201, 10.1016/j.phrs.2024.107086 · DOI
  32. Ahad, 2021, A review on enzyme activated drug delivery system, Res. J. Pharm. Technol., 10.5958/0974-360X.2021.00094.9 · DOI
  33. Liu, 2023, Reactive oxygen species-responsive polymer drug delivery systems, Front. Bioeng. Biotechnol.
  34. Yurkevicz, 2023, Abstract 2715: utilizing a pH sensitive peptide (pHLIP) for tumor targeted delivery of an immunogenic peptide motif, Cancer Res., 10.1158/1538-7445.AM2023-2715 · DOI
  35. Rudko, 2021, Recent developments in ion-sensitive systems for pharmaceutical applications, Polymers, 10.3390/polym13101641 · DOI
  36. Zeng, 2018, Hypoxia-activated prodrugs and redox-responsive nanocarriers, Int. J. Nanomed., 10.2147/IJN.S173431 · DOI
  37. Pan, 2021, Photosensitive drug delivery systems for cancer therapy: mechanisms and applications, J. Contr. Release, 10.1016/j.jconrel.2021.08.053 · DOI
  38. Song, 2020, Thermoresponsive hydrogel induced by dual supramolecular assemblies and its controlled release property for enhanced anticancer drug delivery, Biomacromolecules, 10.1021/acs.biomac.0c00077 · DOI
  39. Entzian, 2021, Drug delivery by ultrasound-responsive nanocarriers for cancer treatment, Pharmaceutics, 13, 1, 10.3390/pharmaceutics13081135 · DOI
  40. Kolosnjaj-Tabi, 2019, Electric field-responsive nanoparticles and electric fields: physical, chemical, biological mechanisms and therapeutic prospects, Adv. Drug Deliv. Rev., 10.1016/j.addr.2018.10.017 · DOI
  41. Xing, 2024, Recent advances in metal-organic frameworks for stimuli-responsive drug delivery, Nanoscale, 10.1039/D3NR05776C · DOI
  42. Uddin, 2023, Modification with conventional surfactants to improve a lipid-based ionic-liquid-associated transcutaneous anticancer vaccine, Molecules, 28, 2969, 10.3390/molecules28072969 · DOI
  43. Md Moshikur, 2022, Transformation of hydrophilic drug into oil-miscible ionic liquids for transdermal drug delivery, ACS Appl. Mater. Interfaces, 14, 55332, 10.1021/acsami.2c15636 · DOI
  44. Islam, 2021, Insulin transdermal delivery system for diabetes treatment using a biocompatible ionic liquid-based microemulsion, ACS Appl. Mater. Interfaces, 13, 42461, 10.1021/acsami.1c11533 · DOI
  45. Kumari, 2023, A review on nanoparticles: smart particles for cancer therapy
  46. Iranpour, 2021, Application of smart nanoparticles as a potential platform for effective colorectal cancer therapy, Coord. Chem. Rev., 10.1016/j.ccr.2021.213949 · DOI
  47. Yang, 2024, Harnessing nanotechnology: emerging strategies for multiple myeloma therapy, Biomolecules, 14, 10.3390/biom14010083 · DOI
  48. Wu, 2023, Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art, J. Nanobiotechnol., 10.1186/s12951-023-01804-7 · DOI
  49. Bai, 2022, Sustained drug release from smart nanoparticles in cancer therapy: a comprehensive review, Micromachines, 10.3390/mi13101623 · DOI
  50. Uddin, 2021, Lipid-based ionic-liquid-mediated nanodispersions as biocompatible carriers for the enhanced transdermal delivery of a peptide drug, ACS Appl. Bio Mater., 4, 6256, 10.1021/acsabm.1c00563 · DOI
  51. Uddin, 2020, Lipid based biocompatible ionic liquids: synthesis, characterization and biocompatibility evaluation, Chem. Commun., 56, 13756, 10.1039/D0CC04491A · DOI
  52. Liang, 2021, Stimuli-responsive drug delivery systems for head and neck cancer therapy, Drug Deliv., 10.1080/10717544.2021.1876182 · DOI
  53. Zhou, 2018, Stimuli-responsive polymeric micelles for drug delivery and cancer therapy, Int. J. Nanomed.
  54. Lao, 2013, Liposomal doxorubicin in the treatment of breast cancer patients: a review, J. Drug Deliv, 1, 10.1155/2013/456409 · DOI
  55. Radu, 2022, Recent advances in stimuli-responsive doxorubicin delivery systems for liver cancer therapy, Polymers, 10.3390/polym14235249 · DOI
  56. Vijayakameswara Rao, 2018, Recent progress and advances in stimuli-responsive polymers for cancer therapy, Front. Bioeng. Biotechnol.
  57. Yang, 2022, CAR-T cell therapy for breast cancer: from basic research to clinical application, Int. J. Biol. Sci., 10.7150/ijbs.70120 · DOI
  58. Kankeu Fonkoua, 2022, CAR T cell therapy and the tumor microenvironment: current challenges and opportunities, Mol. Ther. Oncolytics, 10.1016/j.omto.2022.03.009 · DOI
  59. Zhang, 2023, CAR-T cell therapy in multiple myeloma: current limitations and potential strategies, Front. Immunol.
  60. Caccese, 2019, PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: a concise review, Crit. Rev. Oncol. Hematol., 10.1016/j.critrevonc.2018.12.002 · DOI · Paper page
  61. Li, 2022, PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy, Front. Immunol., 13, 1, 10.3389/fimmu.2022.1070961 · DOI
  62. Mantovani, 2022, Macrophages as tools and targets in cancer therapy, Nat. Rev. Drug Discov., 10.1038/s41573-022-00520-5 · DOI · Paper page
  63. Schepisi, 2023, The new frontier of immunotherapy: chimeric antigen receptor T (CAR-T) cell and macrophage (CAR-M) therapy against breast cancer, Cancers, 15, 1597, 10.3390/cancers15051597 · DOI
  64. Sloas, 2021, Engineered CAR-macrophages as adoptive immunotherapies for solid tumors, Front. Immunol., 10.3389/fimmu.2021.783305 · DOI
  65. Shin, 2023, Recent advances in CAR-based solid tumor immunotherapy, Cells, 10.3390/cells12121606 · DOI
  66. Zhang, 2023, Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy, Front. Bioeng. Biotechnol.
  67. Liu, 2023, Recent advances in targeted gene silencing and cancer therapy by nanoparticle-based delivery systems, Biomed. Pharmacother.
  68. Liu, 2023, Injectable smart stimuli-responsive hydrogels: pioneering advancements in biomedical applications, Biomater. Sci.
  69. Liu, 2023, Angiogenic signaling pathways and anti-angiogenic therapy for cancer, Signal Transduct. Targeted Ther.
  70. Yee Wa, 2024, Genetically engineered mesenchymal stem cells using viral vectors: a new frontier in anti-angiogenic therapy, Sains Malays.
  71. Wang, 2023, Emerging non-viral vectors for gene delivery, J. Nanobiotechnol., 10.1186/s12951-023-02044-5 · DOI
  72. Yadav, 2025, Developing ultra-high concentration formulations of human immune globulins for subcutaneous injectables, J. Pharmaceut. Sci., 1
  73. Guerrache, 2024, TNF-related apoptosis-inducing ligand: non-apoptotic signalling, Cells, 13, 521, 10.3390/cells13060521 · DOI
  74. Liu, 2021, Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics, Precis. Clin. Med., 10.1093/pcmedi/pbab014 · DOI
  75. Gong, 2023, Full thermal ablation versus partial thermal ablation for secondary hyperparathyroidism: a meta-analysis, Médica Sur
  76. Fiorentini, 2023, Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: a multicenter retrospective observational comparative study, World J. Clin. Oncol., 10.5306/wjco.v14.i6.215 · DOI
  77. Séguier, 2024, Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer, Nat. Rev. Urol., 10.1038/s41585-023-00834-y · DOI
  78. Gupta, 2023, Effects of probe parameters on radio-frequency ablation of localized liver cancer using a personalized patient treatment planning, Therm. Sci. Eng. Prog., 10.1016/j.tsep.2023.102236 · DOI
  79. Rosiak, 2023, Microwave ablation of colorectal cancer lung metastases — the first experience in Poland, Oncol. Clin. Pract., 10.5603/OCP.2022.0008 · DOI
  80. Grauer, 2019, Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients, J. Neuro Oncol., 141, 83, 10.1007/s11060-018-03005-x · DOI
  81. Tewari, 2023, Magnetic hyperthermia cancer therapy using rare earth metal-based nanoparticles: an investigation of Lanthanum strontium Manganite's hyperthermic properties, Results Eng, 10.1016/j.rineng.2023.101537 · DOI
  82. Farzanegan, 2023, Evaluating the applications and effectiveness of magnetic nanoparticle-based hyperthermia for cancer treatment: a systematic review, Appl. Radiat. Isot., 10.1016/j.apradiso.2023.110873 · DOI
  83. Fusco, 2024, An informative review of radiomics studies on cancer imaging: the main findings, challenges and limitations of the methodologies, Curr. Oncol., 10.3390/curroncol31010027 · DOI
  84. Wang, 2024, Machine learning for prediction of non-small cell lung cancer based on inflammatory and nutritional indicators in adults: a cross-sectional study, Cancer Manag. Res., 16, 527, 10.2147/CMAR.S454638 · DOI
  85. De Ruysscher, 2022, SP-0522 Radiomics and radiotherapy: state of the art and future challenges, Radiother. Oncol., 10.1016/S0167-8140(22)03980-9 · DOI
  86. Socol, 2023, Artificial intelligence in biology and medicine, and radioprotection research: perspectives from Jerusalem, Front. Artif. Intell.
  87. Ibrahim, 2021, Radiomics for precision medicine: current challenges, future prospects, and the proposal of a new framework, Methods, 10.1016/j.ymeth.2020.05.022 · DOI
  88. Azadi Moghadam, 2024, Artificial intelligence and pathomics: prostate cancer, Urol. Clin., 10.1016/j.ucl.2023.06.001 · DOI
  89. Wu, 2023, Recent advances of pathomics in colorectal cancer diagnosis and prognosis, Front. Oncol.
  90. Foran, 2022, An expandable informatics framework for enhancing central cancer registries with digital pathology specimens, computational imaging tools, and advanced mining capabilities, J. Pathol. Inf., 10.4103/jpi.jpi_31_21 · DOI
  91. Hiremath, 2024, An integrated radiology-pathology machine learning classifier for outcome prediction following radical prostatectomy: preliminary findings, Heliyon, 10, 10.1016/j.heliyon.2024.e29602 · DOI
  92. Hölscher, 2023, Next-Generation Morphometry for pathomics-data mining in histopathology, Nat. Commun., 10.1038/s41467-023-36173-0 · DOI
  93. Mahmud, 2023, The development of eco-friendly biopolymers for use in tissue engineering and drug delivery, J. Nanomater., 10.1155/2023/9270064 · DOI
  94. El-Seedi, 2023, Gelatin nanofibers: recent insights in synthesis, bio-medical applications and limitations, Heliyon, 10.1016/j.heliyon.2023.e16228 · DOI
  95. Li, 2023, Hydrogel systems for targeted cancer therapy, Front. Bioeng. Biotechnol.
  96. Tang, 2024, Intelligent hydrogel-assisted hepatocellular carcinoma therapy, Research, 1
  97. Ren, 2023, Injectable nanomotors-hydrogel system with high cellular uptake for targeted cancer gene therapy, Fuhe Cailiao Xuebao/Acta Mater. Compos. Sin.
  98. Liu, 2022, Recent developments in stimuli-responsive hydrogels for biomedical applications, Biosurface and Biotribology, 10.1049/bsb2.12050 · DOI
  99. Nikolaeva, 2024, Gefitinib: combination therapy and complex delivery systems, Drug Dev. Regist, 10.33380/2305-2066-2024-13-1-1615 · DOI
  100. Islam, 2024, Mechanistic approach to immunity and immunotherapy of alzheimer's disease: a review, ACS Chem. Neurosci., 15, 3589
  101. Woodring, 2023, Drug delivery systems for localized cancer combination therapy, ACS Appl. Bio Mater., 10.1021/acsabm.2c00973 · DOI
  102. Li, 2024, Bacteria-based bioactive materials for tumor immunotherapy, Precis. Med. Eng., 1, 10.1016/j.preme.2024.100013 · DOI
  103. Wang, 2020, Recent progress of chemodynamic therapy-induced combination cancer therapy, Nano Today, 10.1016/j.nantod.2020.100946 · DOI
  104. Attiguppe, 2023, A novel integrated transdermal drug delivery system with micropump and microneedle made from polymers, Micromachines
  105. Donnelly, 2024, The promise of microneedle technologies for drug delivery, Drug Deliv. Transl. Res., 10.1007/s13346-023-01430-8 · DOI
  106. Rahimi, 2023, A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma, Eur. J. Pharmaceut. Sci., 187, 10.1016/j.ejps.2023.106476 · DOI
  107. Wu, 2024, Microneedles as transdermal drug delivery system for enhancing skin disease treatment, Acta Pharm. Sin. B, 14, 5161, 10.1016/j.apsb.2024.08.013 · DOI
  108. Qi, 2023, Smart responsive microneedles for controlled drug delivery, Molecules, 10.3390/molecules28217411 · DOI
  109. Chen, 2023, Strategies to develop polymeric microneedles for controlled drug release, Adv. Drug Deliv. Rev., 10.1016/j.addr.2023.115109 · DOI
  110. Xiao, 2023, Antibody–drug conjugates in breast cancer: ascent to destiny and beyond—a 2023 review, Curr. Oncol., 10.3390/curroncol30070474 · DOI
  111. Li, 2024, Antibody drug conjugates in breast cancer in China: highlights, challenges, and prospects, Cancer
  112. Theocharopoulos, 2021, Antibody-drug conjugates: functional principles and applications in oncology and beyond, Vaccines, 10.3390/vaccines9101111 · DOI
  113. Jahan, 2022, Antibody-drug conjugates for the treatment of HER2-positive breast cancer, Genes, 13, 2065, 10.3390/genes13112065 · DOI
  114. Lee, 2023, Abstract 2710: developing a novel doppel-targeting antibody-drug conjugate (ADC) for solid cancer, Cancer Res.
  115. Juen, 2023, Abstract 2012: a novel antibody-drug conjugate platform enabling high drug-to-antibody ratios and greater payload flexibility, Cancer Res., 10.1158/1538-7445.AM2023-2012 · DOI
  116. Chavda, 2022, Nano-drug delivery systems entrapping natural bioactive compounds for cancer: recent progress and future challenges, Front. Oncol., 10.3389/fonc.2022.867655 · DOI
  117. Ezike, 2023, Advances in drug delivery systems, challenges and future directions, Heliyon, 9, 10.1016/j.heliyon.2023.e17488 · DOI · Paper page
  118. Du, 2021, Cells-based drug delivery for cancer applications, Nanoscale Res. Lett., 10.1186/s11671-021-03588-x · DOI
  119. Zargar, 2019, A review of controlled drug delivery systems based on cells and cell membranes, J. Med. Signals Sens.
  120. Yu, 2023, Emerging frontiers in drug delivery with special focus on novel techniques for targeted therapies, Biomed. Pharmacother., 165, 10.1016/j.biopha.2023.115049 · DOI
  121. Zare, 2021, Carbon nanotubes: smart drug/gene delivery carriers, Int. J. Nanomed.
  122. Sharma, 2021, Toxicology of nanoparticles in drug delivery, Curr. Pathobiol. Rep, 10.1007/s40139-021-00227-z · DOI
  123. Luo, 2025, Dual pH-responsive CRISPR/Cas9 ribonucleoprotein xenopeptide complexes for genome editing, Eur. J. Pharmaceut. Sci., 205, 10.1016/j.ejps.2024.106983 · DOI
  124. Redrup Hill, 2023, Ethical and legal considerations influencing human involvement in the implementation of artificial intelligence in a clinical pathway: a multi-stakeholder perspective, Front. Digit. Heal., 5, 1
  125. Sharma, 2024, Understanding the challenges associated with approval of anticancer products to facilitate the regulatory approvals: a cross-sectional study, Curr. Cancer Ther. Rev., 10.2174/0115733947273426231128054645 · DOI
  126. Moll, 2023, Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysis, Front. Public Health, 10.3389/fpubh.2023.1016860 · DOI
  127. Boby, 2021, Financial toxicity in cancer care in India: a systematic review, Lancet Oncol., 10.1016/S1470-2045(21)00468-X · DOI
  128. Chisholm, 2007, Cost of scaling up mental healthcare in low- and middle-income countries, Br. J. Psychiatry, 191, 528, 10.1192/bjp.bp.107.038463 · DOI · Paper page
  129. James, 2024, The Lancet Commission on prostate cancer: planning for the surge in cases, Lancet, 403, 1683, 10.1016/S0140-6736(24)00651-2 · DOI
  130. Hassan, 2020, A deliberative study of public attitudes towards sharing genomic data within NHS genomic medicine services in England, Publ. Understand. Sci., 10.1177/0963662520942132 · DOI
  131. Ahmed, 2023, Patients' perspectives related to ethical issues and risks in precision medicine: a systematic review, Front. Med., 10.3389/fmed.2023.1215663 · DOI
  132. Kourelis, 2023, Ethical challenges with multiple myeloma bcma chimeric antigen receptor T cell slot allocation: a multi-institution experience. Transplant, Cell. Ther
  133. Ward, 2021, Challenges and opportunities in cancer drug resistance, Chem. Rev., 10.1021/acs.chemrev.0c00383 · DOI
  134. Rodrigues, 2022, Drug repurposing in cancer therapy: influence of patient's genetic background in breast cancer treatment, Int. J. Mol. Sci.
  135. Wu, 2023, Supramolecular host-guest nanosystems for overcoming cancer drug resistance, Cancer Drug Resist, 10.20517/cdr.2023.77 · DOI
  136. Fessart, 2024, Mechanisms of cancer drug resistance, Bull. Cancer
  137. Veninga, 2021, Tumor organoids: opportunities and challenges to guide precision medicine, Cancer Cell, 10.1016/j.ccell.2021.07.020 · DOI · Paper page
  138. Jindal, 2023, Long-acting parenteral drug delivery systems for the treatment of chronic diseases, Adv. Drug Deliv. Rev., 10.1016/j.addr.2023.114862 · DOI
  139. Gomathi, 2023, Pulsatile drug delivery: a strategy for treating chronotherapeutic ailments, Int. J. Curr. Pharmaceut. Res.
  140. Hassan, 2022, Phytochemical screening and antidiabetic effects of fruit rind of Momordica dioica roxb. on streptozocin induced type 2 diabetic rats, Heliyon, 8, 10.1016/j.heliyon.2022.e08771 · DOI
  141. Uddin, 2016, Amaranthus viridis modulates anti-hyperglycemic pathways in hemi-diaphragm and improves glycogenesis liver function in rats, J. Pharmacogn. Phyther., 8, 173
  142. Beatty, 2023, Soft robot-mediated autonomous adaptation to fibrotic capsule formation for improved drug delivery, Sci. Robot., 10.1126/scirobotics.abq4821 · DOI
  143. McNicholas, 2023, Translation of obstructive sleep apnea pathophysiology and phenotypes to personalized treatment: a narrative review, Front. Neurol., 10.3389/fneur.2023.1239016 · DOI
  144. Chioma Anthonia, 2024, A comprehensive review of AI applications in personalized medicine, Int. J. Sci. Res. Arch., 10.30574/ijsra.2024.11.1.0338 · DOI
  145. Okolo, 2024, Data-driven approaches to bridging the gap in health communication disparities: A systematic review, World J. Adv. Res. Rev., 21, 1435, 10.30574/wjarr.2024.21.2.0591 · DOI
  146. Eleftheriadis, 2021, Modular design principle based on compartmental drug delivery systems, Adv. Drug Deliv. Rev., 10.1016/j.addr.2021.113921 · DOI
  147. Chehelgerdi, 2023, Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation, Mol. Cancer, 22, 169, 10.1186/s12943-023-01865-0 · DOI
  148. Passaro, 2024, Cancer biomarkers: emerging trends and clinical implications for personalized treatment, Cell, 187, 1617, 10.1016/j.cell.2024.02.041 · DOI
  149. Dey, 2023, Recent advancements, limitations, and future perspectives of the use of personalized medicine in treatment of colon cancer, Technol. Cancer Res. Treat., 10.1177/15330338231178403 · DOI
  150. Sheudeen Abubakar, 2024, Gene therapy advancements for precision cancer treatment: challenges and opportunities in sub-saharan africa – Nigeria perspective, Asian J. Biochem. Genet. Mol. Biol., 10.9734/ajbgmb/2024/v16i1354 · DOI
  151. Ansah, 2022, Ethical challenges and controversies in the practice and advancement of gene therapy, Adv. Cell Gene Ther, 10.1155/2022/1015996 · DOI
  152. Arboleda-García, 2023, Advancements in synthetic biology-based bacterial cancer therapy: a modular design approach, Crit. Rev. Oncol. Hematol., 10.1016/j.critrevonc.2023.104088 · DOI
  153. Celichowski, 2023, Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility, J. Transl. Med., 10.1186/s12967-023-04041-6 · DOI
  154. Hattab, 2021, Clinical advances of sirna-based nanotherapeutics for cancer treatment, Pharmaceutics, 10.3390/pharmaceutics13071009 · DOI
  155. Li, 2024, Multifunctional nanoparticle-mediated combining therapy for human diseases, Signal Transduct. Targeted Ther.
  156. Kurakula, 2023, Emergence of small interfering RNA-based gene drugs for various diseases, ACS Omega, 10.1021/acsomega.3c01703 · DOI
  157. Pareek, 2025, Advancing cancer therapy with quantum dots and other nanostructures : a review of drug delivery innovations , applications , and challenges, Cancer, 17, 878, 10.3390/cancers17050878 · DOI
  158. Weng, 2025, Translocation mechanism of anticancer drugs through membrane with the assistance of graphene quantum dot, Colloids Surf. B Biointerfaces, 245, 10.1016/j.colsurfb.2024.114340 · DOI
  159. Jin, 2025, Engineered bacteria for disease diagnosis and treatment using synthetic biology, Microb. Biotechnol., 18, 1, 10.1111/1751-7915.70080 · DOI
  160. Makong Ekpan, 2023, The synergy of AI and drug delivery: a revolution in healthcare 5 publications 2 citations see profile, Artic. Int. J. Adv. Biol. Biomed. Res., 43–66

Cited by

Sorted by citations

Metadata

Authors
Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., & Uddin, S.
Venue
European Journal of Medicinal Chemistry
Publisher
Elsevier BV
Published
2025-06
Volume
290
Pages
117535
ISSN
0223-5234
DOI
10.1016/j.ejmech.2025.117535
Cited by
119
References
5
Language
en
Licence
Funders
King Fahd University of Petroleum & Minerals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review